Analysts Set Inozyme Pharma, Inc. (NASDAQ:INZY) PT at $11.75

Shares of Inozyme Pharma, Inc. (NASDAQ:INZY - Get Free Report) have been given a consensus rating of "Hold" by the nine analysts that are covering the stock, Marketbeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $11.75.

Several equities research analysts have recently issued reports on INZY shares. Piper Sandler decreased their target price on Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating for the company in a research report on Tuesday, March 11th. Jefferies Financial Group reaffirmed a "hold" rating and set a $4.00 target price (down from $15.00) on shares of Inozyme Pharma in a research report on Friday, May 16th. TD Cowen lowered Inozyme Pharma from a "strong-buy" rating to a "hold" rating in a report on Friday, May 16th. Wall Street Zen raised Inozyme Pharma to a "sell" rating in a report on Saturday. Finally, Wells Fargo & Company reissued an "equal weight" rating and issued a $4.00 price objective on shares of Inozyme Pharma in a report on Friday, May 16th.

Inozyme Pharma Stock Performance

NASDAQ:INZY remained flat at $4.00 during trading hours on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.19 and a quick ratio of 2.19. The firm's fifty day moving average is $3.28 and its 200 day moving average is $2.07. Inozyme Pharma has a twelve month low of $0.72 and a twelve month high of $6.24. The stock has a market cap of $258.25 million, a price-to-earnings ratio of -2.37 and a beta of 2.27.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). As a group, equities research analysts predict that Inozyme Pharma will post -1.59 EPS for the current year.

Institutional Trading of Inozyme Pharma

A number of large investors have recently modified their holdings of the business. Affinity Asset Advisors LLC lifted its position in Inozyme Pharma by 40.7% in the 4th quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock worth $11,003,000 after buying an additional 1,150,000 shares during the last quarter. Sanofi bought a new stake in Inozyme Pharma in the 4th quarter worth approximately $1,228,000. Renaissance Technologies LLC lifted its position in Inozyme Pharma by 155.7% in the 4th quarter. Renaissance Technologies LLC now owns 421,399 shares of the company's stock worth $1,167,000 after buying an additional 256,599 shares during the last quarter. Walleye Capital LLC purchased a new position in Inozyme Pharma in the 4th quarter worth approximately $658,000. Finally, Pale Fire Capital SE increased its stake in Inozyme Pharma by 101.7% in the 1st quarter. Pale Fire Capital SE now owns 440,807 shares of the company's stock worth $401,000 after purchasing an additional 222,270 shares during the period. Institutional investors own 88.30% of the company's stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.